Keyphrases
Adaptive Clinical Trials
68%
Adaptive Randomization
28%
Adaptive Trial
29%
Adaptive Trial Design
37%
Adult Intensive Care Unit
44%
Adult Patients
47%
Antipsychotic-induced Weight Gain
23%
Antipsychotics
23%
Bayesian Analysis
23%
Between-day
23%
Bi-center
23%
Binary Outcome
31%
Clinical Trials
39%
Count Outcomes
23%
COVID-19
62%
Critical Care
67%
Critical Care Trials
49%
Critical Illness
26%
Cytochrome P450 2D6 (CYP2D6)
23%
Days Alive without Life Support
74%
Event Counts
27%
Fluid Restriction
26%
Health-related Quality of Life
60%
Healthcare Data
35%
Heterogeneous Treatment Effects
28%
Hydroxychloroquine
47%
Hyperlactatemia
23%
Individualized Prediction
35%
Intensive Care Unit
42%
Intensive Care Unit Admission
27%
Intensive Care Unit Patients
100%
International Networks
71%
Intravenous Fluid Therapy
26%
Intravenous Fluids
38%
Methodological Choices
27%
Methodological Considerations
33%
Patient Characteristics
29%
Patient Data
27%
Patient Outcomes
27%
Prediction Window
23%
Predictive Enrichment
47%
Randomized Clinical Trial
77%
Randomized Trial
23%
Restrictive Fluid Therapy
23%
Rheumatoid Arthritis
30%
Root Mean Square Error
41%
Scoping Review
95%
Sepsis
26%
Septic Shock
59%
Trial Protocol
47%
Medicine and Dentistry
Adaptive Response
9%
Adverse Event
35%
All Cause Mortality
11%
Arm
35%
Attributable Risk
10%
Azithromycin
23%
Base
6%
Cardiovascular Mortality
6%
Clinical Trial
34%
Cohort Analysis
49%
COVID-19
65%
Critical Illness
26%
Drug Megadose
7%
Drug Therapy
5%
Effect Size
13%
Electronic Patient Record
9%
Fluid Therapy
23%
Glycemic Control
5%
Hazard Ratio
32%
Health Care
23%
Hydroxychloroquine
47%
Hyperglycemia
7%
Hyperlactatemia
23%
Hypoglycemia
7%
Infusion Fluid
32%
Intensive Care
76%
Intensive Care Medicine
23%
Intensive Care Unit
84%
Intravenous Drug Administration
26%
Lactic Acid
8%
Meropenem
23%
Monte Carlo Method
23%
Noradrenalin
23%
Phenotype
23%
Piperacillin/Tazobactam
23%
Post-Hoc Analysis
23%
Proportional Hazards Model
9%
Quality of Life
68%
Randomized Clinical Trial
47%
Randomized Controlled Trial
17%
Retrospective Study
23%
Rheumatoid Arthritis
47%
Rheumatology
7%
Secondary Data
23%
Sepsis
29%
Septic Shock
47%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Statistical Analysis
7%
Tartaric Acid
6%
Treatment Effect
25%
